63 related articles for article (PubMed ID: 15011644)
21. Anti-HIV agents. Access denied--keeping HIV out with entry inhibitors.
TreatmentUpdate; 2006; 18(4):4. PubMed ID: 17205653
[No Abstract] [Full Text] [Related]
22. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
Goebel FD
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
[No Abstract] [Full Text] [Related]
23. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
[TBL] [Abstract][Full Text] [Related]
24. [Combined treatment with fusion inhibitor. HIV-1 viruses under control longer].
MMW Fortschr Med; 2004 Apr; 146(15):68. PubMed ID: 15373030
[No Abstract] [Full Text] [Related]
25. HIV fusion inhibitors.
Qadir MI; Malik SA
Rev Med Virol; 2010 Jan; 20(1):23-33. PubMed ID: 19827030
[TBL] [Abstract][Full Text] [Related]
26. [First fusion inhibitor is available. No entry for HIV-1 viruses].
MMW Fortschr Med; 2003 Jun; 145(25):51. PubMed ID: 12891854
[No Abstract] [Full Text] [Related]
27. A new recombinant virus system for the study of HIV-1 entry and inhibition.
Roman F; Ammerlaan W; Plesseria JM; Deroo S; Muller CP; Arendt V; Schneider F; Hemmer R; Schmit JC
J Virol Methods; 2006 Jan; 131(1):99-104. PubMed ID: 16111774
[TBL] [Abstract][Full Text] [Related]
28. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
[TBL] [Abstract][Full Text] [Related]
29. [New treatments against AIDS: fusion inhibitors].
Holzgrabe U
Pharm Unserer Zeit; 2004; 33(1):6. PubMed ID: 14968706
[No Abstract] [Full Text] [Related]
30. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
[No Abstract] [Full Text] [Related]
31. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.
Stewart KD; Huth JR; Ng TI; McDaniel K; Hutchinson RN; Stoll VS; Mendoza RR; Matayoshi ED; Carrick R; Mo H; Severin J; Walter K; Richardson PL; Barrett LW; Meadows R; Anderson S; Kohlbrenner W; Maring C; Kempf DJ; Molla A; Olejniczak ET
Bioorg Med Chem Lett; 2010 Jan; 20(2):612-7. PubMed ID: 20004576
[TBL] [Abstract][Full Text] [Related]
32. Katy, bar the door! HIV entry inhibitors.
Martinez LJ
Res Initiat Treat Action; 2000 Jun; 6(2):6-12. PubMed ID: 11707878
[No Abstract] [Full Text] [Related]
33. Fuzeon combination highly effective.
AIDS Patient Care STDS; 2006 Dec; 20(12):888. PubMed ID: 17219619
[No Abstract] [Full Text] [Related]
34. Expression and biochemical analysis of the entire HIV-2 gp41 ectodomain: determinants of stability map to N- and C-terminal sequences outside the 6-helix bundle core.
Lay CS; Wilson KA; Kobe B; Kemp BE; Drummer HE; Poumbourios P
FEBS Lett; 2004 Jun; 567(2-3):183-8. PubMed ID: 15178320
[TBL] [Abstract][Full Text] [Related]
35. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
[TBL] [Abstract][Full Text] [Related]
36. [Enfuvirtida (Fuzeon). Laboratory: Roche & Trimeris].
Moreno Alvarez PJ
Farm Hosp; 2003; 27(4):271-2. PubMed ID: 12966457
[No Abstract] [Full Text] [Related]
37. New partnership calls for clinical testing of two fusion inhibitors.
Slovick J
Posit Living; 1999 Aug; 8(7):15, 62. PubMed ID: 12492078
[No Abstract] [Full Text] [Related]
38. [Initial retroviral drug with new mechanism of action. Peptide T-20 enriches therapeutic arsenal].
MMW Fortschr Med; 2003 Apr; 145 Spec No 1():55-7. PubMed ID: 15011591
[No Abstract] [Full Text] [Related]
39. T-20 being called "miraculous".
AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412581
[No Abstract] [Full Text] [Related]
40. Misleading efficacy claims for Fuzeon.
AIDS Patient Care STDS; 2005 Sep; 19(9):614. PubMed ID: 16247841
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
